

# Idiopathic Pulmonary Fibrosis Disease Treatment: Global Markets

<https://marketpublishers.com/r/I2DD7AC56097EN.html>

Date: October 2020

Pages: 60

Price: US\$ 3,950.00 (Single User License)

ID: I2DD7AC56097EN

## Abstracts

### Report Scope:

The current report provides detailed coverage of IPF. This report will provide perspective on the drugs and therapies used for the management of IPF, including forecast trends and sales through 2024. Important manufacturers, technologies and factors influencing demand are discussed.

The market has been segregated geographically into the U.S., Japan and five major European markets (Germany, France, Italy, Spain, and the U.K.). For market estimates, data has been provided for the year 2018 as the base year, 2019 and then forecast for 2024.

### Report Includes:

An overview of the global markets for idiopathic pulmonary fibrosis (IPF) disease treatment

Analyses of the global market trends, with corresponding market analysis data for 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024

Estimation of market size and market share analysis of IPF chronic disease on the basis of type of therapeutics and geography

Insights into the market trends and opportunities, drivers and restraints, regulatory framework, epidemiology, complications, and prevalence of this

chronic lung disease

Company profiles of the market leading participants within the pharmaceuticals industry

## Contents

### **CHAPTER 1 INTRODUCTION**

Reasons for Doing this Study  
Scope of Report  
Information Sources  
Methodology  
Analyst's Credentials  
Related BCC Research Reports

### **CHAPTER 2 SUMMARY AND HIGHLIGHTS**

### **CHAPTER 3 DRUG DEVELOPMENT AND APPROVAL PROCESS**

Introduction  
Drug Discovery Process  
Drug Definition  
Drug Development Regulations  
Classification of Techniques Used in Drug Discovery  
High-Throughput Screening  
Bioanalytical Instruments for Drug Discovery  
Cell-Based Assays and Reagents for Drug Discovery  
Proteomics Drug Discovery Tools  
Genomics Drug Discovery Tools  
Bioinformatics as a Platform for Drug Discovery  
Others: Metabolomics, Combinatorial Chemistry, Systems Biology, and Nanotechnology

### **CHAPTER 4 DISEASE OVERVIEW**

Etiology  
Pathogenesis  
Symptoms  
Comorbidities  
Risk Factors  
Environmental  
Genetic  
Epigenetic Alterations  
Aging

## **CHAPTER 5 DISEASE MANAGEMENT AND TREATMENT**

Diagnosis of Idiopathic Pulmonary Fibrosis

Diagnostic Criteria for IPF

Treatments for IPF

Lifestyle Changes

Oxygen

Medications

Pulmonary Rehabilitation

Lung Transplant

## **CHAPTER 6 MARKETED DRUGS FOR IDIOPATHIC PULMONARY FIBROSIS**

Introduction

Overview of Products

Esbriet Drug Profile

Ofev Drug Profile

## **CHAPTER 7 PRODUCT FORECAST FOR IDIOPATHIC PULMONARY FIBROSIS**

Esbriet (Pirfenidone)

Ofev (Nintedanib)

## **CHAPTER 8 PRODUCT PIPELINE FOR IDIOPATHIC PULMONARY FIBROSIS**

Product Pipeline for Idiopathic Pulmonary Fibrosis

## **CHAPTER 9 APPENDIX: ACRONYMS**

## List Of Tables

### LIST OF TABLES

Table 1: Idiopathic Pulmonary Fibrosis Drug Sales, by Country, Through 2024

Table 2: Main Symptoms of Idiopathic Pulmonary Fibrosis

Table 3: Other Symptoms of Idiopathic Pulmonary Fibrosis

Table 4: Key Drugs Marketed for IPF

Table 5: Esbriet Drug Profile

Table 6: Boehringer Ingelheim GmbH: IPF Product Portfolio

Table 7: Roche: IPF Portfolio

Table 8: Roche: IPF Pipeline Portfolio

Table 9: Ofev Drug Profile

Table 10: Sales of Esbriet for IPF, 2018-2024

Table 11: Number of IDF Patients Using Esbriet, 2018-2024

Table 12: Sales of Ofev for IPF, 2018-2024

Table 13: Number of IPF Patients Using Ofev, 2018-2024

Table 14: Phase III Pipeline Products in Development for IPF

Table 15: Acronyms Used in This Report

## List Of Figures

### LIST OF FIGURES

Figure 1: Drug Discovery Process

Figure 2: Schematic View of IPF Pathogenesis

Figure 3: Diagnostic Algorithm for IPF

Figure 4: Boehringer Ingelheim GmbH: Annual Revenue, 2015-2019

Figure 5: Boehringer Ingelheim GmbH: Revenue Shares, by Business Unit, 2019

Figure 6: Boehringer Ingelheim GmbH: Revenue Shares, by Region, 2019

Figure 7: Roche: Annual Revenue, 2018 and 2019

Figure 8: Roche: Revenue Share, by Product Category, 2019

## I would like to order

Product name: Idiopathic Pulmonary Fibrosis Disease Treatment: Global Markets

Product link: <https://marketpublishers.com/r/l2DD7AC56097EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l2DD7AC56097EN.html>